Evidence map›Paper›PMID 25869245›Full record

ArticleXenobiotica; the fate of foreign compounds in biological systems2015

Irreversible binding of an anticancer compound (BI-94) to plasma proteins.

Nagsen Gautam, Rhishikesh Thakare, Sandeep Rana, Amarnath Natarajan, Yazen Alnouti

Abstract read
In one paragraph

Article in Xenobiotica; the fate of foreign compounds in biological systems, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nagsen Gautama Department of Pharmaceutical Sciences , ollege of Pharmacy, University of Nebraska Medical Center , Omaha , NE , USA and.
Rhishikesh Thakare
Sandeep Rana
Amarnath Natarajan
Yazen Alnouti

Funding

Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ALNOUTI, YAZEN · 2010 to 2019
$16.8M
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeuticsR01CA127239 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI NATARAJAN, AMARNATH (AMAR) · 2008 to 2012
$1.5M
NCI NIH HHS CA127239NCI NIH HHS R01 CA127239NIDA NIH HHS DA028555-01NIDA NIH HHS P01 DA028555
6 · The paper itself

Abstract

1. We investigated the mechanisms responsible for the in vivo instability of a benzofurazan compound BI-94 (NSC228148) with potent anti-cancer activity. 2. BI-94 was stable in MeOH, water, and in various buffers at pHs 2.5-5, regardless of the buffer composition. In contrast, BI-94 was unstable in NaOH and at pHs 7-9, regardless of the buffer composition. BI-94 disappeared immediately after spiking into mice, rat, monkey, and human plasma. BI-94 stability in plasma can be only partially restored by acidifying it, which indicated other mechanisms in addition to pH for BI-94 instability in plasma. 3. BI-94 formed adducts with the trapping agents, glutathione (GSH) and N-acetylcysteine (NAC), in vivo and in vitro via nucleophilic aromatic substitution reaction. The kinetics of adduct formation showed that neutral or physiological pHs enhanced and accelerated GSH and NAC adduct formation with BI-94, whereas acidic pHs prevented it. Therefore, physiological pHs not only altered BI-94 chemical stability but also enhanced adduct formation with endogenous nucleophiles. In addition, adduct formation with human serum albumin-peptide 3 (HSA-T3) at the Cys34 position was demonstrated. 4. In conclusion, BI-94 was unstable at physiological conditions due to chemical instability and irreversible binding to plasma proteins.

Indexed as

AcetylcysteineAnimalsAntineoplastic AgentsBlood ProteinsDrug StabilityGlutathioneHumansHydrogen-Ion ConcentrationMaleMice, Inbred BALB CMolecular StructureOxadiazolesSerum AlbuminSulfonesTandem Mass SpectrometryAcetylcysteineAntineoplastic AgentsBlood ProteinsGlutathioneNSC228148OxadiazolesSerum AlbuminSulfonesGlutathioneirreversible protein bindingisotopic filteringLC-MS/MSN-acetylcysteine

Identifiers

PMID25869245
PMCPMC4553108

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.